We’re back with another issue of Updates from the Lab! Read on for this month’s breaking news and background on our three research programs.
Breaking News
1. We are thrilled to share that British Columbia has added SCID to its newborn screening program.
“The importance of a robust screening program is paramount to ensuring the future health of newborns,” said Adrian Dix, Minister of Health.
You can read the full press release here: https://news.gov.bc.ca/releases/2022HLTH0197-001536.
2. Pharming Group N.V. announces that the US Food and Drug Administration (FDA) has accepted for priority review its New Drug Application (NDA) for leniolisib, an oral, selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor, to treat the rare primary immunodeficiency activated phosphoinositide 3-kinase delta syndrome (APDS) in adults and adolescents 12 years of age and older in the US.
The FDA has assigned a Prescription Drug User Fee Act (PDUFA) goal date of March 29, 2023, aligned with a Priority Review classification. Read the press release.
Translational Research Program
Final review and consideration for Cycle 10 of our Translational Research program will be taking place in next month! This grant is awarded to investigators researching potential advances in clinical recognition, diagnostic tools, and innovative therapies that will impact overall health outcomes and improve the quality of life of patients living with Primary Immunodeficiency.
Specific Defect
Investigators researching the mechanisms and presentation of specific defects of the immune system will gain access to our international database throughout collaboration efforts as part of the Specific Defect research program. Applications are rolling.
c.h.i.l.d.r.e.n!
We encourage physicians investigating immunological disorders, infectious disease, and initiatives to decrease infant mortality to apply throughout the year for our c.h.i.l.d.r.e.n! research program.